Received Feb 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Spent 2 nights in hospital as a result of this vaccine with a massive flare up requiring heavy medication. Still in pain today; This serious case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 12-FEB-2026, the patient received the 1st dose of Shingrix. In FEB-2026, less than a week after receiving Shingrix, the patient experienced shingles (Verbatim: Spent 2 nights in hospital as a result of this vaccine with a massive flare up requiring heavy medication. Still in pain today) (serious criteria hospitalization). The outcome of the shingles was resolved. It was unknown if the reporter considered the shingles to be related to Shingrix. The company considered the shingles to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 17-FEB-2026 The patient had received the first part of the vaccine last Thursday and was scheduled to receive the second dose in two months. The batch number was not provided, and we are unable to contact the reporter; Sender's Comments: A case of Herpes zoster, less than a week after receiving the 1st dose of Shingrix, in a patient. Based on the available information, a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.